Deltec Asset Management LLC Makes New Investment in Kronos Bio, Inc. (NASDAQ:KRON)

Deltec Asset Management LLC bought a new stake in Kronos Bio, Inc. (NASDAQ:KRON) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 200,000 shares of the company’s stock, valued at approximately $190,000. Deltec Asset Management LLC owned about 0.33% of Kronos Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

Kronos Bio Stock Up 1.2 %

Shares of NASDAQ KRON opened at $0.99 on Wednesday. The business has a fifty day simple moving average of $0.98 and a two-hundred day simple moving average of $0.99. The firm has a market cap of $59.78 million, a PE ratio of -0.69 and a beta of 1.80. Kronos Bio, Inc. has a twelve month low of $0.69 and a twelve month high of $1.60.

Analysts Set New Price Targets

Several analysts recently commented on the company. TD Cowen cut Kronos Bio from a “buy” rating to a “hold” rating in a report on Thursday, November 14th. Piper Sandler downgraded Kronos Bio from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $6.00 to $1.00 in a report on Thursday, November 14th.

Kronos Bio Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.